Back to Report Store Home

Hereditary Hematological Disorders Drug Development Pipeline Review, 2018

  • Published: Oct-2018
  • Report Code: GBIHC048IDB
  • Report Format: pdf

Description

List of Tables

Table 1: Number of Products under Development for Thalassemia

Table 2: Number of Products under Development by Companies, Thalassemia

Table 3: Number of Products under Development by Universities/Institutes, Thalassemia

Table 4: Products under Development by Companies, Thalassemia

Table 5: Products under Development by Universities/Institutes, Thalassemia

Table 6: Number of Products under Development for Hemophilia B

Table 7: Number of Products under Development by Companies, Hemophilia B

Table 8: Number of Products under Development by Universities/Institutes, Hemophilia B

Table 9: Products under Development by Companies, Hemophilia B

Table 10: Products under Development by Universities/Institutes, Hemophilia B

Table 11: Number of Products under Development for Sickle Cell Disease

Table 12: Number of Products under Development by Companies, Sickle Cell Disease

Table 13: Number of Products under Development by Universities/Institutes, Sickle Cell Disease

Table 14: Products under Development by Companies, Sickle Cell Disease

Table 15: Products under Development by Universities/Institutes, Sickle Cell Disease

Table 16: Number of Products by Stage and Target, Thalassemia

Table 17: Number of Products by Stage and Mechanism of Action, Thalassemia

Table 18: Number of Products by Stage and Route of Administration, Thalassemia

Table 19: Number of Products by Stage and Molecule Type, Thalassemia

Table 20: Number of Products by Stage and Target, Hemophilia B

Table 21: Number of Products by Stage and Mechanism of Action, Hemophilia B

Table 22: Number of Products by Stage and Route of Administration, Hemophilia B

Table 23: Number of Products by Stage and Molecule Type, Hemophilia B

Table 24: Number of Products by Stage and Target, H2 2018, Sickle Cell Disease

Table 25: Number of Products by Stage and Mechanism of Action, Sickle Cell Disease

Table 26: Number of Products by Stage and Route of Administration, Sickle Cell Disease

Table 27: Number of Products by Stage and Molecule Type, Sickle Cell Disease

Table 28: Thalassemia – Pipeline by Acceleron Pharma Inc

Table 29: Thalassemia – Pipeline by Agios Pharmaceuticals Inc

Table 30: Thalassemia – Pipeline by bluebird bio Inc

Table 31: Thalassemia – Pipeline by Cadila Healthcare Ltd,

Table 32: Thalassemia – Pipeline by Calimmune Inc

Table 33: Thalassemia – Pipeline by CRISPR Therapeutics

Table 34: Thalassemia – Pipeline by Editas Medicine Inc

Table 35: Thalassemia – Pipeline by Errant Gene Therapeutics LLC

Table 36: Thalassemia – Pipeline by Gamida Cell Ltd

Table 37: Thalassemia – Pipeline by Gilead Sciences Inc

Table 38: Thalassemia – Pipeline by Incyte Corp

Table 39: Thalassemia – Pipeline by Ionis Pharmaceuticals Inc

Table 40: Thalassemia – Pipeline by Kiadis Pharma NV

Table 41: Thalassemia – Pipeline by La Jolla Pharmaceutical Company

Table 42: Thalassemia – Pipeline by Merck & Co Inc

Table 43: Thalassemia – Pipeline by Poseida Therapeutics Inc

Table 44: Thalassemia – Pipeline by Protagonist Therapeutics Inc

Table 45: Thalassemia – Pipeline by Sangamo Therapeutics Inc

Table 46: Thalassemia – Pipeline by Silence Therapeutics Plc

Table 47: Thalassemia – Pipeline by Vifor Pharma AG

Table 48: Hemophilia B – Pipeline by Amarna Therapeutics BV

Table 49: Hemophilia B – Pipeline by Bayer AG

Table 50: Hemophilia B – Pipeline by Bioverativ Inc

Table 51: Hemophilia B – Pipeline by Catalyst Biosciences Inc

Table 52: Hemophilia B – Pipeline by China Biologic Products Inc

Table 53: Hemophilia B – Pipeline by CSL Ltd

Table 54: Hemophilia B – Pipeline by Expression Therapeutics LLC

Table 55: Hemophilia B – Pipeline by GC Pharma

Table 56: Hemophilia B – Pipeline by Genethon SA

Table 57: Hemophilia B – Pipeline by LFB SA

Table 58: Hemophilia B – Pipeline by Logicbio Therapeutics Inc

Table 59: Hemophilia B – Pipeline by Novo Nordisk AS

Table 60: Hemophilia B – Pipeline by OPKO Biologics Ltd

Table 61: Hemophilia B – Pipeline by Pfizer Inc

Table 62: Hemophilia B – Pipeline by Pharming Group NV

Table 63: Hemophilia B – Pipeline by Promethera Biosciences SA

Table 64: Hemophilia B – Pipeline by RegenxBio Inc

Table 65: Hemophilia B – Pipeline by Sangamo Therapeutics Inc

Table 66: Hemophilia B – Pipeline by Sanofi

Table 67: Hemophilia B – Pipeline by Shire Plc

Table 68: Hemophilia B – Pipeline by Spark Therapeutics Inc

Table 69: Hemophilia B – Pipeline by UniQure NV

Table 70: Sickle Cell Disease – Pipeline by Angiocrine Bioscience Inc

Table 71: Sickle Cell Disease – Pipeline by Annexin Pharmaceuticals AB

Table 72: Sickle Cell Disease – Pipeline by ArQule Inc

Table 73: Sickle Cell Disease – Pipeline by Bio Products Laboratory Ltd

Table 74: Sickle Cell Disease – Pipeline by Bioverativ Inc

Table 75: Sickle Cell Disease – Pipeline by bluebird bio Inc

Table 76: Sickle Cell Disease – Pipeline by Bristol-Myers Squibb Co

Table 77: Sickle Cell Disease – Pipeline by Cell Source Inc

Table 78: Sickle Cell Disease – Pipeline by CRISPR Therapeutics

Table 79: Sickle Cell Disease – Pipeline by CSL Ltd

Table 80: Sickle Cell Disease – Pipeline by Editas Medicine Inc

Table 81: Sickle Cell Disease – Pipeline by Epizyme Inc

Table 82: Sickle Cell Disease – Pipeline by Errant Gene Therapeutics LLC

Table 83: Sickle Cell Disease – Pipeline by Fulcrum Therapeutics Inc

Table 84: Sickle Cell Disease – Pipeline by Gamida Cell Ltd

Table 85: Sickle Cell Disease – Pipeline by Genethon SA

Table 86: Sickle Cell Disease – Pipeline by Gilead Sciences Inc

Table 87: Sickle Cell Disease – Pipeline by Global Blood Therapeutics Inc

Table 88: Sickle Cell Disease – Pipeline by Homology Medicines, Inc

Table 89: Sickle Cell Disease – Pipeline by Incyte Corp

Table 90: Sickle Cell Disease – Pipeline by Intellia Therapeutics Inc

Table 91: Sickle Cell Disease – Pipeline by Ironwood Pharmaceuticals Inc

Table 92: Sickle Cell Disease – Pipeline by La Jolla Pharmaceutical Company

Table 93: Sickle Cell Disease – Pipeline by MaxCyte Inc

Table 94: Sickle Cell Disease – Pipeline by Merck & Co Inc

Table 95: Sickle Cell Disease – Pipeline by MimeTech Srl

Table 96: Sickle Cell Disease – Pipeline by Morphogenesis Inc

Table 97: Sickle Cell Disease – Pipeline by NKT Therapeutics Inc

Table 98: Sickle Cell Disease – Pipeline by Novartis AG

Table 99: Sickle Cell Disease – Pipeline by Orphagen Pharmaceuticals Inc

Table 100: Sickle Cell Disease – Pipeline by Oryzon Genomics SA

Table 101: Sickle Cell Disease – Pipeline by Pfizer Inc

Table 102: Sickle Cell Disease – Pipeline by Prolong Pharmaceuticals LLC

Table 103: Sickle Cell Disease – Pipeline by Protagonist Therapeutics Inc

Table 104: Sickle Cell Disease – Pipeline by ReveraGen BioPharma Inc

Table 105: Sickle Cell Disease – Pipeline by Sancilio & Company Inc

Table 106: Sickle Cell Disease – Pipeline by Sangamo Therapeutics Inc

Table 107: Sickle Cell Disease – Pipeline by Syros Pharmaceuticals Inc

Table 108: Thalassemia – Dormant Projects

Table 109: Hemophilia B – Dormant Projects

Table 110: Sickle Cell Disease – Dormant Projects

Table 111: Thalassemia – Discontinued Products

Table 112: Hemophilia B – Discontinued Products

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards